The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy
Open accessAbstract
Abstract Learning Objectives After completing this course, the reader will be able to:Explain the molecular biology of epidermal growth factor receptor (EGFR) function in malignant cells.Recognize the relationships between and functions of the erbB family of related cell membrane receptors.Describe the current status of clinical strategies to inhibit EGFR function in malignant cells. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com There is a need for new, selective anticancer agents that differentiate between malignant and nonmalignant cells. The benefits of such agents would include a higher therapeutic index and lower toxicity than conventional therapies. Although expressed in nonmalignant cells, the epidermal growth factor receptor (EGFR) is highly expressed in a variety of tumors, and its expression correlates with poor response to treatment, disease progression, and poor survival. Evidence for a role for the EGFR in the inhibition and pathogenesis of various cancers has led to the rational design and development of agents that selectively target this receptor. Activation of the EGFR signaling pathway in cancer cells has been linked with increased cell proliferation, angiogenesis, and metastasis, and decreased apoptosis. Preclinical data show that anti-EGFR therapies can inhibit these effects in vitro and in vivo. In addition, preclinical data confirm that many such agents have the potential to increase the effectiveness of current cytotoxic agents. Following accelerated drug development programs, phase III trials are now under way for a number of EGFR-targeted therapies, including the monoclonal antibody IMC-C225 and the EGFR-tyrosine kinase inhibitors ZD1839 (IressaTM) and OSI-774. Thus, the rationale for EGFR-targeted approaches to cancer treatment is apparent and now well established, and there is increasing evidence that they may represent a significant contribution to cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
Burgering, B. M. T., & Coffer, P. J. (1995) · Nature · doi:10.1038/376599a0 · Cited by 2,089
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Self-citationA novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello, F., & Tortora, G. (2001) · PubMed · Cited by 977
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
Single-molecule imaging of EGFR signalling on the surface of living cells
Sako, Y., Minoghchi, S., & Yanagida, T. (2000) · Nature Cell Biology · doi:10.1038/35004044 · Cited by 890
Cited by
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Chromosome aberrations in solid tumors
Albertson, D. G., Collins, C., McCormick, F., & Gray, J. W. (2003) · Nature Genetics · doi:10.1038/ng1215 · Cited by 812
Steuer, C. E., El‐Deiry, M., Parks, J. R., Higgins, K. A., & Saba, N. F. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21386 · Cited by 672
Dittmann, K., Mayer, C., Fehrenbacher, B., Schaller, M., Raju, U., Milas, L., Chen, D. J., Kehlbach, R., & Rodemann, H. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506591200 · Cited by 529
Systemic Treatment of Colorectal Cancer
Wolpin, B. M., & Mayer, R. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.098 · Cited by 504
EGFR Signaling and Drug Discovery
Lurje, G., & Lenz, H.-J. (2009) · Oncology · doi:10.1159/000279388 · Cited by 442
Tyrosine phosphorylation controls PCNA function through protein stability
Wang, S.-C., Nakajima, Y., Yu, Y.-L., Xia, W., Chen, C.-T., Yang, C.-C., McIntush, E. W., Li, L.-Y., Hawke, D. H., Kobayashi, R., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1501 · Cited by 322
Signaling through the epidermal growth factor receptor during the development of malignancy
Grandis, J. R., & Sok, J. C. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.01.002 · Cited by 320
Atkins, D., Reiffen, K.-A., Tegtmeier, C. L., Winther, H., Bonato, M. S., & Störkel, S. (2004) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.3a6195.2004 · Cited by 319
Adjuvant Treatment of Colorectal Cancer
Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., & Mayer, R. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.3.168 · Cited by 306
Cancer invasion and metastasis: changing views
Duffy, M., McGowan, P., & Gallagher, W. (2008) · The Journal of Pathology · doi:10.1002/path.2282 · Cited by 302
Focus on epithelial ovarian cancer
Ozols, R. F., Bookman, M. A., Connolly, D. C., Daly, M. B., Godwin, A. K., Schilder, R. J., Xu, X., & Hamilton, T. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00002-9 · Cited by 294
EGFR associated expression profiles vary with breast tumor subtype
Hoadley, K. A., Weigman, V. J., Fan, C., Sawyer, L. R., He, X., Troester, M. A., Sartor, C. I., Rieger-House, T., Bernard, P. S., Carey, L. A., et al. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-258 · Cited by 278
Hiscox, S., Morgan, L., Green, T. P., Barrow, D., Gee, J., & Nicholson, R. I. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9120-9 · Cited by 274
Efferth, T. (2007) · Planta Medica · doi:10.1055/s-2007-967138 · Cited by 269
Vincenzi, B., Santini, D., Russo, A., Gavasci, M., Battistoni, F., Dicuonzo, G., Rocci, L., Rosaria, V. M., Gebbia, N., & Tonini, G. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.4.319 · Cited by 38
Wheler, J. J., Tsimberidou, A. M., Falchook, G. S., Zinner, R. G., Hong, D. S., Fok, J. Y., Fu, S., Piha-Paul, S. A., Naing, A., & Kurzrock, R. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1208 · Cited by 34
In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells
Luca, T., Barresi, V., Privitera, G., Musso, N., Caruso, M., Condorelli, D. F., & Castorina, S. (2014) · Cell Proliferation · doi:10.1111/cpr.12125 · Cited by 27
Kamashev, D., Shaban, N., Lebedev, T., Prassolov, V., Suntsova, M., Raevskiy, M., Gaifullin, N., Sekacheva, M., Garazha, A., Poddubskaya, E., et al. (2023) · Cells · doi:10.3390/cells12162022 · Cited by 14
Metadata
- Authors
- Baselga, J.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-08-15
- Volume
- 7
- Issue
- 90004
- Pages
- 2-8
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2169332099
- Cited by
- 510
- References
- 35
- FWCI
- 15.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.